RENE GONZALEZ to MAP Kinase Kinase 2
This is a "connection" page, showing publications RENE GONZALEZ has written about MAP Kinase Kinase 2.
Connection Strength
0.372
-
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
Score: 0.169
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
Score: 0.103
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
Score: 0.100